Ionis Plunges 23% on Trial Failure, Investor Scrutiny Mounts

What happened

Ionis stock fell 23% on July 9 after its partner AstraZeneca announced failure of the CARDIO-TTRansform trial for eplontersen in heart disease. The surprise miss has triggered an investigation by Hagens Berman into possible securities law violations. Despite the setback, Ionis reaffirmed 2026 revenue guidance of $875-900 million, supported by its owned commercial launches TRYNGOLZA and DAWNZERA. The company holds $1.9 billion in cash and has two near-term regulatory catalysts: zilganersen PDUFA on September 22 and bepirovirsen on October 26. The stock now trades at $58, below the report's attractive entry of $52, but the bear case at $45 suggests further downside if commercial execution falters.

Implication

The CARDIO-TTRansform failure removes a key partnered upside leg and shifts more value burden to Ionis's owned pipeline. The $58 price already discounts some risk, but the bear case of $45 is plausible if TRYNGOLZA sHTG launch shows payer access friction or zilganersen fails. The report maintains a POTENTIAL BUY rating with conviction 3.5, but the margin of safety depends on liquidity rather than earnings durability. Key checkpoints are the next quarterly update for TRYNGOLZA sales, zilganersen PDUFA in September, and bepirovirsen in October. If these catalysts succeed, the stock could re-rate; if not, the balance sheet cushion may not protect valuation.

Thesis delta

The trial failure reduces the perceived diversification of Ionis's pipeline and places greater weight on the success of TRYNGOLZA and zilganersen. This shifts the investment thesis from a diversified platform bet to a more binary near-term catalyst play, though the report's favorable entry and cash position still support a tactical buy.